



PRODUCT: Oxbryta® (voxelotor) tablets

COMPANY: Global Blood Therapeutics, Inc. (GBT)

THERAPEUTIC AREA & INDICATION:

Prevents inherited propensity for
the hemoglobin polymerization
that causes sickle cell disease

ABOUT THE PRODUCT

Oxbryta® (voxelotor) tablets is a hemoglobin S polymerization inhibitor indicated for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older. This indication is approved under accelerated approval based on increase in hemoglobin. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). SCD is a rare genetic blood disorder that affects nearly 100,000 people in the United States, primarily of African descent, and millions worldwide. For more information, including Important Safety Information, please visit: <https://oxbryta.com/pdf/prescribing-information.pdf>.